{"id":141710,"title":"Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T22:26:58.262000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=true","snippet":"Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP) - Canada.ca Skip to main content Skip to \"About government\" Language selection Français fr / Gouvernement…","rawSnapshotUrl":"/api/snapshots/raw/141710","browseUrl":"https://replay.healtharchive.ca/job-1/20250418222658/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/notice-considerations-proposed-use-psilocybin-mushrooms-clinical-trials-special-access-program.html?wbdisable=true#ha_snapshot=141710","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}